Cite
Rhododendrol‐induced leukoderma update II: Pathophysiology, mechanisms, risk evaluation, and possible mechanism‐based treatments in comparison with vitiligo.
MLA
Inoue, Shintaro, et al. “Rhododendrol‐induced Leukoderma Update II: Pathophysiology, Mechanisms, Risk Evaluation, and Possible Mechanism‐based Treatments in Comparison with Vitiligo.” Journal of Dermatology, vol. 48, no. 7, July 2021, pp. 969–78. EBSCOhost, https://doi.org/10.1111/1346-8138.15878.
APA
Inoue, S., Katayama, I., Suzuki, T., Tanemura, A., Ito, S., Abe, Y., Sumikawa, Y., Yoshikawa, M., Suzuki, K., Yagami, A., Masui, Y., Ito, A., & Matsunaga, K. (2021). Rhododendrol‐induced leukoderma update II: Pathophysiology, mechanisms, risk evaluation, and possible mechanism‐based treatments in comparison with vitiligo. Journal of Dermatology, 48(7), 969–978. https://doi.org/10.1111/1346-8138.15878
Chicago
Inoue, Shintaro, Ichiro Katayama, Tamio Suzuki, Atsushi Tanemura, Shosuke Ito, Yuko Abe, Yasuyuki Sumikawa, et al. 2021. “Rhododendrol‐induced Leukoderma Update II: Pathophysiology, Mechanisms, Risk Evaluation, and Possible Mechanism‐based Treatments in Comparison with Vitiligo.” Journal of Dermatology 48 (7): 969–78. doi:10.1111/1346-8138.15878.